APGE vs LIN · $2.34B cap vs P/E 34, rev $18.07B
Apogee Therapeutics, Inc. Common Stock (APGE) versus Linde plc Ordinary Shares (LIN) — a side-by-side from cached financials, not a winner call.
Apogee Therapeutics, Inc. Common Stock (APGE) is a biotechnology company listed on US.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
APGE does not have a complete income-statement cache yet.
Latest reported LIN revenue for 2026-06-30 was $18.07B. Net income was $3.79B. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
APGE currently screens at market cap $2.34B. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Not investment advice. Open the APGE and LIN stock pages for the full models.
Not investment advice.